Musculoskeletal Transplant Foundation Inc.
$2.1M 3,503 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
TELA Bio, Inc.
TELA Bio, Inc. reported $2,067,848.25 across General Payments, Research, and Ownership to 7,569 physicians and teaching hospitals across 7,569 transactions.
- $2.1M Top quartile payer
- All-tracks total
- 7,569 Top quartile volume
- Transactions
- 7,569 Top quartile reach
- Recipients
- −$79.4K
- General Payments vs PY2023
TELA Bio, Inc. reported $2,067,848.25 across all CMS Open Payments tracks (General + Research + Ownership) to 7,569 physicians and teaching hospitals in Program Year 2024 - ranking #441 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,067,848.25, averaging $273.20 per recipient.
TELA Bio, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
56/100
Total payments
F
29/100
Transaction volume
C
65/100
Physician reach
C
67/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer tela-bio-inc TELA Bio, Inc.
$2.1M · #441/1,925 · 0.0% industry · PY2024
- TOT $2.1M
- RANK #441
- SHARE 0.0%
- TXN 7,569
- RCP 7,569
- CAT 5
- GEN $2.1M
- ΔGEN −$79.4K
- TOP1 17.5%
- PY 2024
Volume peers
Nearest volume peer: Musculoskeletal Transplant Foundation Inc. ($2.1M)
TELA Bio, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
TELA Bio, Inc.'s CMS-reported General Payments decreased by $79.4K (−3.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: TELA BIO, INC.PY2023: TELA BIO, INC.PY2024: TELA Bio, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,147,267.48
- PY2024
- $2,067,848.25
What the Data Shows for TELA Bio, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For TELA Bio, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 5-category general-payment breakdown below at $1.3M (64.4% of General Payments, 187 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads TELA Bio, Inc.'s 5-category general-payment breakdown at $1.3M, 64.4% of the reported total.
TELA Bio, Inc. reports 5 general-payment categories - the top three are Consulting Fee (64.4%), Food and Beverage (20.3%), and Travel and Lodging (15.2%). The remaining 2 categories make up 0.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How TELA Bio, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.3M | 187 | 64.4% |
| Food and Beverage | $420.1K | 6,858 | 20.3% |
| Travel and Lodging | $314.5K | 522 | 15.2% |
| Grant | $1.5K | 1 | 0.1% |
| Education | $895.00 | 1 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $823,336.08 (39.8%) of $2,067,848.25 in this company's General Payments records across 3,105 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for TELA Bio, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Paul P Szotek Jr.
$361,650.58 across 102 reported transactions
- 2
Jorge L Florin
$234,237.08 across 28 reported transactions
- 3
Samir S Awad
$82,505.59 across 35 reported transactions
- 4
Salvatore J Pacella III
$76,447.86 across 33 reported transactions
- 5
Ian L Valerio
$68,494.97 across 58 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
TELA Bio, Inc. ranks #441 of 1,925 by total payments (top 23% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,271 of 1,838 by HHI (bottom 31% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Rattan And Associates : $17.3K total payments, HHI 548
- Apellis Pharmaceuticals, Inc. : $3.5M total payments, HHI 546
- Abanza Inc. : $3.5K total payments, HHI 546
- Pajunk Medical Systems, LP : $4.4K total payments, HHI 538
- Cagent Vascular INC : $103.5K total payments, HHI 534
- ImmunoGen, Inc. : $95.7K total payments, HHI 533
- TELA Bio, Inc. (this company) : $2.1M total payments, HHI 531
- Medistim USA, Inc. : $4.8K total payments, HHI 530
- Catheter Precision Inc. : $1.3K total payments, HHI 525
- Centinel Spine, LLC : $742.0K total payments, HHI 525
- Roche Diagnostics International Ltd : $376.3K total payments, HHI 524
- Life Spine, Inc. : $327.4K total payments, HHI 523
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as TELA Bio, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about TELA Bio, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with TELA Bio, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Avadel CNS Pharmaceuticals, LLC
$2.1M 9,568 recipients
Compare payment profiles
Recor Medical Inc
$2.1M 2,012 recipients
Compare payment profiles
Miach Orthopaedics, Inc.
$2.1M 1,054 recipients
Compare payment profiles
ClearPoint Neuro, Inc.
$2.1M 467 recipients
Compare payment profiles
Pediatric Alliance LLC
$2.1M 26 recipients
Compare payment profiles
Put this to use
TELA Bio, Inc. ranks #441 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where TELA Bio, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just TELA Bio, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.